tiprankstipranks
Advertisement
Advertisement

OCS Stock Latest News

Oculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage Testing
Company AnnouncementsOculis Advances Targeted Dry Eye Drug Licaminlimab Into Late-Stage Testing
4d ago
OCS
Oculis Sets May 13, 2026 AGM in Zug and Schedules Shareholder Info Session
PremiumCompany Announcements
Oculis Sets May 13, 2026 AGM in Zug and Schedules Shareholder Info Session
8d ago
6K
OCS
Oculis Buy Rating Reiterated on De-Risked Phase 3 DIAMOND Program and Blockbuster Potential of Topical DME Therapy OCS-01
PremiumRatings
Oculis Buy Rating Reiterated on De-Risked Phase 3 DIAMOND Program and Blockbuster Potential of Topical DME Therapy OCS-01
9d ago
OCS
Oculis Holding: Needham Conference Visibility Reinforces Buy Rating and Upside Potential
PremiumRatings
Oculis Holding: Needham Conference Visibility Reinforces Buy Rating and Upside Potential
14d ago
OCS
Three new option listings on March 17th
PremiumThe Fly
Three new option listings on March 17th
1M ago
OCS
GBFH
Oculis price target raised to $50 from $40 at Stifel
PremiumThe FlyOculis price target raised to $50 from $40 at Stifel
2M ago
OCS
Oculis Files 2025 Financials and Renews $100 Million ATM Program
Premium
Company Announcements
Oculis Files 2025 Financials and Renews $100 Million ATM Program
2M ago
6K
OCS
Oculis files automatic mixed securities shelf
Premium
The Fly
Oculis files automatic mixed securities shelf
2M ago
OCS
Oculis price target raised to $44 from $42 at H.C. Wainwright
PremiumThe Fly
Oculis price target raised to $44 from $42 at H.C. Wainwright
2M ago
OCS
Oculis: Advancing Late-Stage Ophthalmology Pipeline Drives Upside and Supports Buy Rating
PremiumRatings
Oculis: Advancing Late-Stage Ophthalmology Pipeline Drives Upside and Supports Buy Rating
2M ago
OCS
Oculis: Strengthened Balance Sheet and Advancing Late-Stage Pipeline Support Buy Rating and Higher $40 Target Ahead of 2026 Pivotal Readouts
PremiumRatings
Oculis: Strengthened Balance Sheet and Advancing Late-Stage Pipeline Support Buy Rating and Higher $40 Target Ahead of 2026 Pivotal Readouts
2M ago
OCS
Oculis Posts 2025 Results, Extends Cash Runway and Advances Late-Stage Ophthalmology Pipeline
PremiumCompany Announcements
Oculis Posts 2025 Results, Extends Cash Runway and Advances Late-Stage Ophthalmology Pipeline
2M ago
6K
OCS
Oculis reports Q4 EPS (CHF 0.42c) vs. (CHF 0.67) last year
PremiumThe FlyOculis reports Q4 EPS (CHF 0.42c) vs. (CHF 0.67) last year
2M ago
OCS
Oculis Holding Ag (OCS) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Oculis Holding Ag (OCS) Q4 Earnings Cheat Sheet
2M ago
OCS
J.P. Morgan Bangs the Drum on These 2 ‘Strong Buy’ Stocks
Premium
Stock Analysis & Ideas
J.P. Morgan Bangs the Drum on These 2 ‘Strong Buy’ Stocks
4M ago
GTX
OCS
Oculis (OCS): Privosergtor’s Breakthrough Profile in Optic Neuritis Supports First-in-Class Upside and Buy Rating
PremiumRatings
Oculis (OCS): Privosergtor’s Breakthrough Profile in Optic Neuritis Supports First-in-Class Upside and Buy Rating
4M ago
OCS
Oculis: Strengthening Clinical and Regulatory Momentum Supports Buy Rating and $42 Target
PremiumRatings
Oculis: Strengthening Clinical and Regulatory Momentum Supports Buy Rating and $42 Target
4M ago
OCS
Morning Movers: OneStream surges following report of Hg takeover talks
PremiumThe Fly
Morning Movers: OneStream surges following report of Hg takeover talks
4M ago
OS
DHI
Oculis up 9% after announcing breakthrough therapy designation for Privosegtor
PremiumThe Fly
Oculis up 9% after announcing breakthrough therapy designation for Privosegtor
4M ago
OCS
Oculis price target raised to $40 from $35 at Stifel
PremiumThe FlyOculis price target raised to $40 from $35 at Stifel
4M ago
OCS
Oculis initiated with an Overweight at JPMorgan
Premium
The Fly
Oculis initiated with an Overweight at JPMorgan
4M ago
OCS
Oculis initiated with an Outperform at LifeSci Capital
Premium
The Fly
Oculis initiated with an Outperform at LifeSci Capital
5M ago
OCS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >